目的：本研究旨在运用 C 反应蛋白（CRP）作为全身及肿瘤局部炎症反应的参数，分析其与新辅助化疗前后乳腺癌患者的临床病理生物学因素之间的关系及其对新辅助化疗疗效的影响。方法本研究回顾性分析了我院乳腺外科2001年1月至2010年6月确诊并接受新辅助化疗的Ⅱ－Ⅲ期乳腺癌患者共215例。按不同的病理完全缓解（pCR）标准分组（包括原发灶和淋巴结及仅包括原发灶），统计学分析 CRP 与新辅助化疗患者的临床病理特征及病理完全缓解（pCR）之间的关系。结果达到 pCR 的患者较非 pCR 患者的 CRP 均值更低（P＝0．035和 P＝0．032），CRP 对pCR（仅包括原发灶）有良好的预测价值（P＜0．001）。结论新辅助化疗前 CRP 水平有助于预测新辅助化疗疗效。%Objective To analyze the relationship between C reactive protein (CRP) and clinical pathobiiology factors before and after neoadjuvant chemotherapy. Methods This research retrospectively analyzed 215 patients , who were diagnosed as breast cancer in stage Ⅱ-Ⅲ, admitted in the Breast Cancer Department of our hospital and accepted NAC in January 2001 to June 2010. The relationship of CRP with clinicopathological characteristics as well as efficacy of prediction of pathologic complete response according to two different standards were statistically analyzed. Results Patients with pCR were in lower CRP value comparing with non-pCR patients. CRP reached a high efficacy in predicting pCR (the absence of all invasive disease in the breast tumor ). Conclusion The protein level of CRP shows predictive value of pCR with neoadjuvantchemotherapy patients.
展开▼
